- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07763418
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85225
- Recruiting
- Arizona Clinical Trials - Chandler
-
Contact:
- Anita Kohli, Site 0003
- Phone Number: 434-825-0921
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- Recruiting
- Panax Clinical Research
-
Contact:
- Robert Perry, Site 0002
- Phone Number: 305-698-4500
-
Orlando, Florida, United States, 32809-3017
- Recruiting
- Orlando Clinical Research Center OCRC
-
Contact:
- Thomas Marbury, Site 0001
- Phone Number: 407-257-3462
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must have severe renal impairment (RI).
- Participant must have end-stage renal disease (ESRD).
- Participant must be healthy male and female participants not of childbearing potential between 18 and 84 years of age (inclusive) with a BMI between 18 and 40 kg/m2, (inclusive) at screening.
Exclusion Criteria:
- Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
- Known or suspected active autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
- Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A
|
Specified dose on specified days
Other Names:
|
|
Experimental: Group B
|
Specified dose on specified days
Other Names:
|
|
Experimental: Group C
|
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed concentration (Cmax)
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Time of maximum observed plasma concentration (Tmax)
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time Frame: Up to Day 44
|
Up to Day 44
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with adverse events (AEs)
Time Frame: Up to Day 60
|
Up to Day 60
|
|
Number of participants with serious adverse events (SAEs)
Time Frame: Up to Day 60
|
Up to Day 60
|
|
Number of participants with physical examination (PE) abnormalities
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Number of participants with vital sign abnormalities
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Number of participants with clinical safety laboratory abnormalities
Time Frame: Up to Day 44
|
Up to Day 44
|
|
Dialysate clearance of golcadomide from plasma (CLD)
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Pathological Conditions, Signs and Symptoms
- Kidney Failure, Chronic
Other Study ID Numbers
- CA073-1033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.